NILOTINIB HCL
ANTINEOPLASTIC - PROTEIN-TYROSINE KINASE INHIBITORS · CHRONIC PHASE PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOCYTIC LEUKEMIA ·+1
NOVADOZ PHARMAC
Drug class
Antineoplastic - Protein-Tyrosine Kinase Inhibitors
Antineoplastic protein-tyrosine kinase inhibitors are a targeted therapeutic class of predominantly small-molecule agents designed to treat diverse malignancies. Read more about Antineoplastic - Protein-Tyrosine Kinase Inhibitors
170 drugs in this class 83 manufacturers
Drugs in Antineoplastic - Protein-Tyrosine Kinase Inhibitors
HYRNUO (sevabertinib)
ANTINEOPLASTIC - PROTEIN-TYROSINE KINASE INHIBITORS · HER2 POSITIVE NON-SQUAMOUS NON-SMALL CELL LUNG CANCER W/ TYROSINE KINASE DOMAIN ACTIVATING MUTATIONS
Bayer HealthCare
DASATINIB
ANTINEOPLASTIC - PROTEIN-TYROSINE KINASE INHIBITORS · PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA ·+4
LUPIN PHARMACEU
NILOTINIB HCL
ANTINEOPLASTIC - PROTEIN-TYROSINE KINASE INHIBITORS · CHRONIC PHASE PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOCYTIC LEUKEMIA ·+1
TORRENT PHARMAC
DASATINIB
ANTINEOPLASTIC - PROTEIN-TYROSINE KINASE INHIBITORS · PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA ·+4
AVKARE
GLEEVEC (imatinib mesylate)
ANTINEOPLASTIC - PROTEIN-TYROSINE KINASE INHIBITORS · PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA ·+11
Novartis Pharmaceuticals
RYDAPT (midostaurin)
ANTINEOPLASTIC - PROTEIN-TYROSINE KINASE INHIBITORS · ACUTE MYELOID LEUKEMIA WITH FMS-LIKE TYROSINE KINASE-3 (FLT3) MUTATION ·+3
Novartis Pharmaceuticals
SCEMBLIX (asciminib hydrochloride)
ANTINEOPLASTIC - PROTEIN-TYROSINE KINASE INHIBITORS · CHRONIC PHASE PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOCYTIC LEUKEMIA ·+1
Novartis Pharmaceuticals
TABRECTA (capmatinib hydrochloride)
ANTINEOPLASTIC - PROTEIN-TYROSINE KINASE INHIBITORS · NON-SMALL CELL LUNG CANCER WITH MESENCHYMAL-EPITHELIAL TRANSITION (MET) EXON 14 SKIPPING
Novartis Pharmaceuticals
Filter & compare in the drug finder →
Opens the drug finder with Antineoplastic - Protein-Tyrosine Kinase Inhibitors preselected. Add indication or manufacturer filters there.
Antineoplastic protein-tyrosine kinase inhibitors are a targeted therapeutic class of predominantly small-molecule agents designed to treat diverse malignancies.
They function by competitively inhibiting the adenosine triphosphate (ATP)–binding sites or allosteric regulatory domains of receptor and non-receptor tyrosine kinases, thereby disrupting downstream intracellular signaling cascades essential for oncogenic cell proliferation, survival, and angiogenesis.
Clinically, these agents play a foundational role in managing both hematologic neoplasms, such as chronic myeloid leukemia, and a broad range of solid tumors, including non-small cell lung cancer, renal cell carcinoma, gastrointestinal stromal tumors, and breast cancer.
-
nih.gov
Antineoplastic protein-tyrosine kinase inhibitors are a targeted therapeutic class of predominantly small-molecule agents designed to treat diverse malignancies Clinically, these agents play a foundational role in managing both hematologic neoplasms, such as chronic myeloid leukemia, and a broad range of solid tumors, including non-small cell lung cancer, renal cell carcinoma, gastrointestinal stromal tumors, and breast cancer
-
nih.gov
Antineoplastic protein-tyrosine kinase inhibitors are a targeted therapeutic class of predominantly small-molecule agents designed to treat diverse malignancies They function by competitively inhibiting the adenosine triphosphate (ATP)–binding sites or allosteric regulatory domains of receptor and non-receptor tyrosine kinases, thereby disrupting downstream intracellular signaling cascades essential for oncogenic cell proliferation, survival, and angiogenesis
-
nih.gov
They function by competitively inhibiting the adenosine triphosphate (ATP)–binding sites or allosteric regulatory domains of receptor and non-receptor tyrosine kinases, thereby disrupting downstream intracellular signaling cascades essential for oncogenic cell proliferation, survival, and angiogenesis
-
rxlist.com
Clinically, these agents play a foundational role in managing both hematologic neoplasms, such as chronic myeloid leukemia, and a broad range of solid tumors, including non-small cell lung cancer, renal cell carcinoma, gastrointestinal stromal tumors, and breast cancer
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.